Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, like the makers of Xarelto, have a duty to ensure that their drugs are reasonably safe for use – and failure to do so might be grounds for compensation. Our lawyers are working difficult to acquire those hurt by the drug the compensation they are entitled to.
Whilst bleeding is a widespread complication associated with anticoagulants, it has been alleged that Xarelto is much more hazardous than standard blood thinners simply because no antidote exists to reverse its blood-thinning effects. This signifies that, within the event of an emergency, sufferers might be at risk for irreversible bleeding troubles, which includes life-threatening internal and gastrointestinal hemorrhaging.
If you or a loved one suffered a severe bleeding event after taking Xarelto, you might have legal recourse. For a lot more data, make contact with us nowadays to possess your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for previous and future health-related bills, lost wages, pain and suffering and, in instances of death, funeral expenses. In addition, they may be in search of punitive damages, which are generally awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto blood thinner lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs inside the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for much more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.